MIOX

Across TCGA pan-cancer cohorts, MIOX Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MIOX data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher MIOX Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIOX expression acts as an unfavorable survival marker.

ESCA, UCEC, and SKCM are the cancer types where MIOX Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.164	0.687	.002	21	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	IV	0.415	0.861	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MIOX–ESCA (OS)

Open the ESCA breakdown →